Literature DB >> 438794

Presentation of the steroid psychoses.

R C Hall, M K Popkin, S K Stickney, E R Gardner.   

Abstract

This study suggests that patients receiving daily doses of 40 mg of prednisone or its equivalent, are at greater risk for developing steroid psychosis. Psychotic reactions were twice as likely to occur during the first 5 days of treatment as subsequently. Premorbid personality, history of previous psychiatric disorder, and a history of previous steroid psychosis did not clearly increase the patient's risk of developing psychotic reaction during any given course of therapy. Steroid psychoses present as spectrum psychoses with symptoms ranging from affective through schizophreniform to those of an organic brain syndrome. No characteristic stable presentation was observed in these 14 cases reported here. The most prominent symptom constellation to appear some time during the course of the illness consisted of emotional lability, anxiety, distractibility, pressured speech, sensory flooding, insomnia, depression, perplexity, agitation, auditory and visual hallucinations, intermittent memory impairment, mutism, disturbances of body image, delusions, apathy, and hypomania. Phenothiazines administered in average daily doses of 212 mg produced excellent response in all patients studied. Of particular note was the fact that tricyclic antidepressants produced an exacerbation or worsening of the clinical state in all patients to whom they were administered.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 438794     DOI: 10.1097/00005053-197904000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  41 in total

1.  Health care use and quality of life among patients with asthma and panic disorder.

Authors:  Jonathan M Feldman; Paul M Lehrer; Soo Borson; Teal S Hallstrand; Mahmood I Siddique
Journal:  J Asthma       Date:  2005-04       Impact factor: 2.515

Review 2.  Adverse neurologic effects of glucocorticosteroids.

Authors:  D Lacomis; M A Samuels
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

Review 3.  Delirium in hospitalized elderly.

Authors:  J Francis; W N Kapoor
Journal:  J Gen Intern Med       Date:  1990 Jan-Feb       Impact factor: 5.128

Review 4.  Epidemiology and management of neuropsychiatric disorders in Behçet's syndrome.

Authors:  Rosaria Talarico; Laura Palagini; Anna d'Ascanio; Elena Elefante; Claudia Ferrari; Chiara Stagnaro; Chiara Tani; Angelo Gemignani; Mauro Mauri; Stefano Bombardieri; Marta Mosca
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

Review 5.  Corticosteroid-induced adverse events in adults: frequency, screening and prevention.

Authors:  Laurence Fardet; Abdulrhaman Kassar; Jean Cabane; Antoine Flahault
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission.

Authors:  P V Piazza; M Barrot; F Rougé-Pont; M Marinelli; S Maccari; D N Abrous; H Simon; M Le Moal
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 7.  Corticosteroids and Cognition: A Meta-Analysis.

Authors:  Catherine E Prado; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2019-05-26       Impact factor: 7.444

8.  Do glucocorticoids induce addiction in humans?

Authors:  R Giordano; F Guaraldi; M Mazzoli; E Ghigo
Journal:  J Endocrinol Invest       Date:  2017-03-25       Impact factor: 4.256

9.  Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Authors:  Erminia Ridolo; P Kihlgren; I Pellicelli; M C Nizi; F Pucciarini; C Incorvaia
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 10.  Corticosteroid-induced neuropsychiatric disorders: review and contrast with neuropsychiatric lupus.

Authors:  Samir D Bhangle; Neil Kramer; Elliot D Rosenstein
Journal:  Rheumatol Int       Date:  2013-04-16       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.